<p>ON THE PEN RESOURCES AND LINKS: <a href="HTTPS://WWW.OTPLINKS.COM" target="_blank" rel="noopener noreferer">HTTPS://WWW.OTPLINKS.COM</a></p><p><br></p><p>What if the most powerful obesity drug ever created ends up being the one you can’t get?</p><p>That’s the real conversation around retatrutide right now.</p><p>In this video, I break down what Eli Lilly is doing behind the scenes, and why this isn’t just about whether retatrutide is better than tirzepatide. This is about strategy. This is about access. And this is about who gets left behind.</p><p>We’re talking about:<br>• The push to classify retatrutide as a biologic<br>• Why that could mean pricing in the $7,000/month range<br>• How LillyDirect is changing access to tirzepatide<br>• The “two lane” system that could define obesity treatment going forward<br>• And what this means for patients already struggling to stay on GLP-1 therapies</p><p>If you’ve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what you’re allowed to have… this one is for you.</p><p>👇 Let’s talk about it<br>Have you ever felt stuck between “this is working” and “this isn’t enough”… with no clear path forward?</p><p><br></p><p><br></p>